Johnson & Johnson vs Protagonist Therapeutics, Inc
JNJ vs PTGX — side-by-side comparison from reported financials. JNJ leads 5, PTGX leads 4 of 9 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Protagonist Therapeutics, Inc
PTGX · Healthcare
$143.00+2.21%Strong
| Metric | JNJ | PTGX |
|---|---|---|
| Price | $261.79 | $143.00 |
| Market cap | $631B | $9.25B |
| Revenue (TTM) | $97.9B | $275M |
| Revenue growth | +5.6% | +20.1% |
| Net margin | 21.5% | 30.2% |
| Free cash flow | $22.2B | $131M |
| Net cash (debt) | ($27.8B) | — |
| 1-year price return | +37.0% | +113.3% |
| P/E | 29.9 | 112.2 |
| P/E vs own history (cheap-side %) | 16% | 21% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | 12% |
| Altman Z-score | — | 139.54 |
| CV checks passed | 10 of 11 | 6 of 11 |
| Employees | 140,800 | 141 |
Full résumé-style profiles: JNJ CV · PTGX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.